Holen Sie sich die Stockscreener-App
4.34
5.86%
-0.27
Vorhandelsmarkt:
4.35
0.010
+0.23%
Trisalus Life Sciences Inc Aktie (TLSI) Neueste Nachrichten
FDA Clears TriNav Advance for Expanded Liver Embolization Access - CancerNetwork
TriSalus Life Sciences Shares Rise After Receiving FDA Clearance for TriNav Advance - marketscreener.com
TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support - TradingView
TriSalus Life Sciences Price Target Raised to $12.00/Share From $11.00 by HC Wainwright & Co. - Moomoo
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday - Benzinga
TriSalus Life Sciences Shares Rise 15.6% After FDA Clearance for TriNav Advance - Yahoo Finance
H.C. Wainwright raises TriSalus stock price target on FDA approval By Investing.com - Investing.com Australia
H.C. Wainwright raises TriSalus stock price target on FDA approval - Investing.com
TLSI Looks 31.8% Overvalued on GF Value™ After FDA Nod for TriNa - GuruFocus
HC Wainwright & Co. maintains Buy rating on TriSalus Life Sciences, $12 price target - TradingView
Why is TriSalus Life Sciences stock surging today? By Investing.com - Investing.com Canada
TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization - BioSpace
TriSalus Life shares surge 29% on FDA device clearance By Investing.com - Investing.com South Africa
Trisalus Life Sciences Receives FDA Clearance For Trinav Advance - TradingView
TriSalus receives FDA clearance for TriNav Advance device By Investing.com - Investing.com Australia
TriSalus Gains FDA Clearance for TriNav Advance Device - TipRanks
TriSalus receives FDA clearance for TriNav Advance device - Investing.com
TLSI: Innovative tumor therapy delivery, rapid growth, and new product launches drive future outlook - TradingView
TriSalus Life Sciences, Inc. Stock Price Prediction: Today, Tomorrow, Next Week (TLSI) - Traders Union
This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
TriSalus Life Sciences (TLSI) Climbs 1.55% as Support Holds Above $4.99Wyckoff Distribution - vinanet.vn
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference - Business Wire
TriSalus Life Sciences (TLSI) Slips 2% as Shares Test Key $4.59 Support LevelKey Reversal Day - dars.gov.et
TriSalus (TLSI) Results Review: The Bottom-Line Figure Trails Its Comparison in the Available Record; Share Response: Shares Move 3.04% Lower in the Latest SessionWeak Earnings Momentum - vinanet.vn
TriSalus (TLSI) Market: Falls 2.18% to $5.16 on the Day; Technical Setup: the Near-Term Reference Band Stretches From $4.90 to $5.42 on the DayETF NAV Deviation - vinanet.vn
TriSalus (TLSI) Latest: Finishes 1.90% Lower at $5.17 at the Close; Next Test: the Near-Term Reference Band Stretches From $4.91 to $5.43Arms Index - dars.gov.et
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates - Eastern Progress
TriSalus (TLSI) Latest Quarter: The Bottom-Line Figure Trails Its Comparison for This Review; Price Move: Shares Finish 2.47% Up in the Current UpdateSegment Revenue Breakdown - vinanet.vn
TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference - MarketBeat
TriSalus Life Sciences (NASDAQ:TLSI) Cut to "Sell" at Wall Street Zen - MarketBeat
TriSalus Life Sciences Warrant (TLSIW) Plunges 55%: Critical Support Test at $0.53AAII Bullish - vinanet.vn
CCORF Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
TriSalus Life Sciences Inc (TLSI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Trisalus Life Sciences at Canaccord Genuity: growth bets build By Investing.com - Investing.com Nigeria
Trisalus Life Sciences at Canaccord Genuity: growth bets build - Investing.com
TriSalus Life Sciences (TLSI) Advances 2.87% as Shares Hold Above $5.45 SupportETH Profile - dars.gov.et
Maxim Group Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Raises Target Price to $14 - Moomoo
TLSI Q2 2026 Earnings: EPS Misses Slightly as Liver-Tumor Focus ContinuesHealthcare Earnings Report - dars.gov.et
TriSalus Life Sciences (TLSI) Dips 4.3% to $5.37 as Shares Approach Key Support ZoneHigh Yield Stocks - careplusvn.com
TriSalus Life Sciences earnings missed by $0.01, revenue topped estimates - Investing.com Canada
TriSalus Life Sciences (TLSI) Stock Surges As Losses Deepen Behind Strong Margins - Sahm
Securities Fraud Investigation Into TriSalus Life Sciences Inc - The National Law Review
TriSalus Life Sciences, Inc. (TLSI) stock price, news, quote and history - Yahoo Finance UK
TriSalus Life Sciences (NASDAQ:TLSI) Posts Quarterly Earnings Results, Meets Expectations - MarketBeat
TriSalus Life Sciences, Inc. Revenue Breakdown – NASDAQ:TLSIW - TradingView
TriSalus Life Sciences Q2 Earnings Call Highlights - marketbeat.com
Price to earnings forward of TriSalus Life Sciences, Inc. – NASDAQ:TLSIW - TradingView
TriSalus Life Sciences Warrant (TLSIW) Slumps 24% to $1.26 as Sellers Dominate the TapeLeveraged ETF Flow - careplusvn.com
TriSalus Life Sciences Inc (TLSI) (Q2 2026) Earnings Call Highlights: New CMS G-code Expands ... - Yahoo Finance
Earnings call transcript: TriSalus tops Q2 revenue forecast, stock slips after hours - Investing.com
Price to sales forward of TriSalus Life Sciences, Inc. – NASDAQ:TLSIW - TradingView
TriSalus Life Sciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
TLSI: Q2 revenue rose to $11.4M, with expanded OBL reimbursement and strong growth outlook - TradingView
TriSalus Q2 2026 Earnings: Gross Margin Rises as Operating Loss Widens - TradingKey
TriSalus Life Sciences, Inc. 2026: Revenue $11.41M, EPS ($0.16) — 10-Q Summary - TradingView
TriSalus Life Sciences Reports Second Quarter 2026 Results - marketscreener.com
Inside TriSalus Life Sciences (NASDAQ: TLSI) Q2 2026 performance - Stock Titan
TriSalus Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
TLSI: Q2 revenue up 1.7% to $11.4M, gross margin 88%, and 2026 guidance reaffirmed at $54–$57M - TradingView
1.51%
0.97%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):